Apollomics (APLM) Equity Ratio (2021 - 2025)

Apollomics (APLM) reported Equity Ratio of 0.47 for Q4 2025, up 91.9% quarter-over-quarter from 5.86 in Q4 2022.

Apollomics (APLM) Equity Ratio (2021 - 2025) Analysis & Trends

Apollomics (APLM) has 3 years of Equity Ratio data on file, last reported at 0.47 in Q4 2025.

  • Equity Ratio for Q4 2025 came in at 0.47, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 0.47 (changed N/A YoY), and the FY2025 annual result was 0.47, changed N/A from the prior year.
  • Equity Ratio grew to 0.47 in Q4 2025 per APLM's latest filing, from 5.86 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.47 in Q4 2025 and troughed at 5.86 in Q4 2022.
  • A 3-year average of 2.69 and a median of 1.72 in 2021 frame the typical range for Equity Ratio.
  • On a YoY basis, Equity Ratio climbed as much as 239.8% in 2022 and fell as far as 239.8% in 2022.
  • A 3-year view of Equity Ratio shows it stood at 1.72 in 2021, then plunged by 239.8% to 5.86 in 2022, then soared by 91.9% to 0.47 in 2025.
  • Business Quant data shows APLM's Equity Ratio at 0.47 in Q4 2025, 5.86 in Q4 2022, and 1.72 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - 191.07
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - 0.98
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - 0.04
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 0.58
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - 0.42
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - -
7 Psyence Biomedical 241.78 Bn 241.78 Bn - -
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn 0.73
9 Abivax 94.26 Bn 94.26 Bn - 0.79
10 Apollomics 294.00 Mn 294.00 Mn - -0.47

Historic Data

Download Data
DateValue
Dec 31, 2025 -0.47
Dec 31, 2022 -5.86
Dec 31, 2021 -1.72